purposes. Representatives of that company pointed out that their cells are not guaranteed to be free from bacterial and viral infections to the standards that would be required for medical use.
The BBC program also alleges that Advanced Cell Therapeutics tried to obscure the origin of the cells by storing them in the UK, using the services of companies that were led to believe that these cells were for research purposes only. Following the revelations, however, this route is likely to be blocked, as the medical use of such cells would be illegal in the UK and even their handling and storage for other purposes than research might violate the Human Tissues Act drawn up in response to the organ retention scandals (Curr. Biol. 14, R254).
"It is important not to judge the potential future benefits of stem cell biology from the actions of those who have shown such flagrant disregard for the lives of their patients."
In a global market, however, people will continue to find ways of offering dubious medicine, using internet marketing and legal loopholes in countries around the world. Advanced Cell Therapeutics, for example, has been carrying out its treatments in Ireland until recently, and, when the authorities stepped in, there were press reports suggesting that the company offered the treatment on board a ferry, in international waters instead.
Similarly, the company Medra, based in Malibu, California, offers injections of "human fetal stem cells" to treat diseases ranging from Alzheimer's through to ulcerative colitis, to be carried out in the Dominican Republic. The company's fact sheet guards tactful silence on the origin of these cells.
Fairchild concludes: "While the practice of companies such as Advanced Cell Therapeutics and Medra is truly shocking, it is important not to judge the potential future benefits of stem cell biology from the actions of those who have shown such flagrant disregard for the lives of their patients."
So, is there any real hope for patients with chronic disease to benefit from stem cell therapies in the near future? Most treatment options that are being investigated in the lab right now will need many years before they might reach the patient. However, there is some more promising, if cautious, news on stem cells. The company Geron, based at Menlo Park, California, is testing a range of stem cell treatments in preclinical trials, and is expecting to start the first Phase I clinical trial early next year, which will most likely involve a possible treatment for acute spinal cord injury.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk Claims about the potential clinical benefit of human stem cells are not the only problem emerging from rapid developments in biology. The use of DNA analyses is proving a tempting target for many companies. There is no doubt that the sequencing of the human genome was a spectacular achievement, announced by President Clinton in 2000. But many commentators then glossed over the difficulties that lay ahead in transferring that information into useful medical advances. So far, despite an explosion of research into how our genetic make-up puts us at risk of disease and affects our reaction to drugs or environmental toxins, there have been few concrete changes in the way doctors administer healthcare.
But companies looking to cash in by analysing DNA don't have the same caution. Do your genes make you metabolise coffee and alcohol more quickly than most people? Are you prone to osteoporosis and Alzheimer's in old age? Do you have the potential for sporting greatness? Plenty are willing to answer, if you are prepared to pay.
There's just one problem: the genetic testing services available at present can't give you that power -though they might aspire to, or insist they can.
Their fallibility was uncovered by a US Government Accountability Office investigation this summer. Over nearly a year, the GAO's investigators anonymously approached four online companies for testing services. They posed as 14 different would-be consumers with a variety of profiles such as age, weight, smoking and exercise habits. In reality, they sent samples of DNA provided from just two people -a 48-year-old man and a nine-month-old girl.
The GAO's report shows that the companies, which charged between $89 and $395 for the tests, provided inconsistent results and offered vague and misleading advice to their supposed clients. One offered supposedly tailored nutritional supplements costing up to $1,200 per year; they turned out to be run-of-the-mill multivitamin tablets that could be bought on the high street for $35 a year.
The companies to whom the samples were sent were: Suracell from Montclair, Sciona Inc. of Boulder, Colorado, Genaissance Pharmaceuticals of Newton, Massachusetts, and Genox and Genelex Corp. of Seattle -and all deny any impropriety.
The GAO said: "Although some types of diseases, such as cystic fibrosis, can be definitively diagnosed by looking at certain A US study of some companies offering DNA analysis has raised concerns. Nigel Williams reports.
Worries over consumer gene tests
genes, the experts the GAO spoke with said that the medical predictions in the test results can not be medically proven at this time." "Even if the predictions could be medically proven, the way the results are presented renders them meaningless. For example, many people 'may' be at 'increased risk' for developing heart disease, so such an ambiguous statement could relate to any human that submitted DNA."
The GAO also said that unproven predictions made by companies "may needlessly alarm consumers into thinking that they have an illness or that they need to buy costly supplements in order to prevent an illness. Perhaps even more troubling, the test results may falsely assure consumers that they are healthy when this may not be the case."
The report's authors said: "Despite the implication that these predictions are based on the DNA submitted, none […] contained scientific support to assist the consumer in evaluating their credibility." Genetics experts told the GAO that none of the sites' predictions about links between genes and health -with osteoporosis, heart disease, diabetes, cancer, or cholesterol and toxin metabolism -could be medically proved at present. Furthermore one nutritionist flagged the level of vitamin B6 in some recommended products as 'disturbing', while another felt there were high levels of vitamin A and that one site's supplements contained excessive iron, which could remain in the blood and become toxic.
One of the companies tested by the GAO has since ceased offering services in the UK following a negative review by the Human Genetics Commission in 2003. But even if these developments have provided a hiccup in company approach to genetic data, DNA is still considered to offer a new front in medicine: pharmacogenetics. This aims to understand how genetic make-up affects the reaction to specific drugs.
With it, doctors could match treatments to patients to speed up cures and minimalise negative reactions to medication. Old drugs abandoned because of adverse effects in some test patients could be revived, if there is a genetic base to the response that would not affect other patients.
But one concern with the cost of developing new medicines is that if genetic studies indicated that only a proportion of potential patients were likely to benefit from a drug, then its development may seem less attractive.
But the prospect is still promising. The anti-cancer drug newly in use, herceptin, works well only against tumours expressing particular genes. It is likely that other successful therapies will follow this line.
